NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by ...

Novo Nordisk is teaming up with Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Here's a recap of the week's most important stories. NVO to Co-Develop Septerna's Oral Therapies for Obesity/Diabetes Novo Nordisk signed a licensing deal with Septerna to co-develop oral therapies ...